METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS: ETIOLOGY, AT-RISK POPULATIONS AND TREATMENT
Makaleler > Tam Makale · 2010
Yazarlar: Mine HOŞGÖR LİMONCU, Şafak ERMERTCAN, Hüseyin TAŞLI, Bayrı ERAÇ, Ayse Nur YURTMAN
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): ETIOLOGY, AT-RISK POPULATIONS AND TREATMENT, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2010, ss 329-364
DOI: 10.1128/aac.01902-17
Özet
After beta-lactamase resistant antibiotics, including methicillin, nafcillin and cephalosporins had been introduced to the clinical use; the first methicillin-resistant Staphylococcus aureus (MRSA) isolates were described in 1961. Since then, MRSA clones have become a problem in health-care institutions throughout the world. Community acquired MRSA (CA-MRSA) isolates have also threatened human health for the last two decades. In multicentral surveillance studies, MRSA prevalence was determined as 1-2 % in North European countries but it may reach up to 80 % in some Far East countries.